Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Enleofen Bio Pte.

    Client Virtual Booth

    ENLEOFEN BIO PTE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Enleofen Bio Pte
    Singapore Flag
    Country
    Country
    Singapore
    Address
    Address
    160 Robinson Road, SBF Centre, # 23-02, Singapore 068914
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.enleofen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enleofen
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

    Details:

    BI 765423 is the first-in-class IL-11 inhibitor antibody, which is being developed in partnership with Enleofen for the treatment of fibrotic diseases.


    Lead Product(s): BI 765423

    Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BI 765423

    Highest Development Status: Phase IProduct Type: Large molecule

    Recipient: Boehringer Ingelheim GmbH

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 09, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

    Details:

    Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.


    Lead Product(s): Enx108A

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

    Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million

    Deal Type: Partnership January 09, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search